{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:43Z","timestamp":1792788343346,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["814027281"],"award-info":[{"award-number":["814027281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773533"],"award-info":[{"award-number":["81773533"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803321"],"award-info":[{"award-number":["81803321"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81761128006"],"award-info":[{"award-number":["81761128006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2018YFC1315504"],"award-info":[{"award-number":["2018YFC1315504"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>How to best triage human papillomavirus (HPV)\u00a0positive women remains controversial in an era of HPV primary screening of cervical cancer. Here, we assessed the long-term risk stratification for triaging HPV 16\u00a0positive women by standalone HPV 16 methylation and combined with E6 oncoprotein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\u00a0A total of 1742 women underwent screening with HPV DNA testing, cytology, and visual inspection with acetic acid (VIA) in 2005 and were followed for 10\u2009years. Seventy-seven women with HPV 16 positivity determined by HPV genotyping test were examined via E6 oncoprotein detection and bisulfite pyrosequencing for quantitative methylation of L1 and LCR genes of HPV 16.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 10-year cumulative incidence rate (CIR) of cervical intraepithelial neoplasia grade 3 or severe (CIN3+) for HPV 16 positive women was 25.3% (95% CI 14.7\u201337.3%), which significantly increased in women with high methylation at six sites (CpG 5602, 6650, 7034, 7461, 31, and 37) and in women with positive E6 oncoprotein. A methylation panel based on the above six sites showed a competitive risk stratification compared to cytology (HR 11.5 vs. 8.1), with a higher 10-year CIR of CIN3+ in panel positives (57.2% vs 36.8%) and comparable low risk in panel negatives (5.7% vs 4.8%).The sensitivity and specificity for accumulative CIN3+ was 85.7% (95%CI 60.1\u201396.0%) and 78.4% (95%CI 62.8\u201388.6%) for a methylation panel and 57.1% (95%CI 32.6\u201378.6%) and 86.5% (95%CI 72.0\u201394.1%) for E6 oncoprotein. The AUC values of methylation standalone\u00a0and the co-testing of methylation panel and E6 oncoprotein were around 0.80, comparable to 0.68 for cytology, 0.65 for viral load, and superior to 0.52 for VIA (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicated the\u00a0promising use of HPV 16 methylation alone or combined with E6 oncoprotein for triaging HPV 16 positive women\u00a0based on the long-term risk stratification ability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-020-00853-1","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T07:03:17Z","timestamp":1588834997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Li","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Lian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin-Jing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Lin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"853_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Munoz","year":"2003","unstructured":"Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518\u201327.","journal-title":"N Engl J Med"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jcp.55.4.244","volume":"55","author":"FX Bosch","year":"2002","unstructured":"Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244\u201365.","journal-title":"J Clin Pathol"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1470-2045(10)70256-4","volume":"11","author":"FH Zhao","year":"2010","unstructured":"Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160\u201371.","journal-title":"Lancet Oncol"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524\u201332.","journal-title":"Lancet."},{"key":"853_CR6","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","volume":"370","author":"NW Bulkmans","year":"2007","unstructured":"Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764\u201372.","journal-title":"Lancet."},{"key":"853_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ijc.31261","volume":"143","author":"K Cuschieri","year":"2018","unstructured":"Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, et al. Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018;143:735\u201345.","journal-title":"Int J Cancer"},{"key":"853_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(12)70568-5","volume":"14","author":"N Wentzensen","year":"2013","unstructured":"Wentzensen N. Triage of HPV-positive women in cervical cancer screening. Lancet Oncol. 2013;14:107\u20139.","journal-title":"Lancet Oncol"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"11172","DOI":"10.1128\/JVI.78.20.11172-11186.2004","volume":"78","author":"BA Van Tine","year":"2004","unstructured":"Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, et al. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol. 2004;78:11172\u201386.","journal-title":"J Virol"},{"key":"853_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000450595","volume":"60","author":"AT Lorincz","year":"2016","unstructured":"Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer prevention. Acta Cytol. 2016;60:501\u201312.","journal-title":"Acta Cytol"},{"key":"853_CR11","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1158\/1055-9965.EPI-12-0905","volume":"21","author":"MA Clarke","year":"2012","unstructured":"Clarke MA, Wentzensen N, Mirabello L, Ghosh A, Wacholder S, Harari A, et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomark Prev. 2012;21:2125\u201337.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ijc.27750","volume":"132","author":"L Mirabello","year":"2013","unstructured":"Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer. 2013;132:1412\u201322.","journal-title":"Int J Cancer"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.virol.2015.06.008","volume":"484","author":"V Simanaviciene","year":"2015","unstructured":"Simanaviciene V, Popendikyte V, Gudleviciene Z, Zvirbliene A. Different DNA methylation pattern of HPV16, HPV18 and HPV51 genomes in asymptomatic HPV infection as compared to cervical neoplasia. Virology. 2015;484:227\u201333.","journal-title":"Virology."},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/jnci\/djs135","volume":"104","author":"L Mirabello","year":"2012","unstructured":"Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst. 2012;104:556\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/infdis\/jiw645","volume":"215","author":"C Kottaridi","year":"2017","unstructured":"Kottaridi C, Kyrgiou M, Pouliakis A, Magkana M, Aga E, Spathis A, et al. Quantitative measurement of L1 human papillomavirus type 16 methylation for the prediction of preinvasive and invasive cervical disease. J Infect Dis. 2017;215:764\u201371.","journal-title":"J Infect Dis"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13148-018-0445-8","volume":"10","author":"L Liu","year":"2018","unstructured":"Liu L, Ying C, Zhao Z, Sui L, Zhang X, Qian C, et al. Identification of reliable biomarkers of human papillomavirus 16 methylation in cervical lesions based on integration status using high-resolution melting analysis. Clin Epigenetics. 2018;10:10.","journal-title":"Clin Epigenetics"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000444585","volume":"82","author":"M Niyazi","year":"2017","unstructured":"Niyazi M, Sui S, Zhu K, Wang L, Jiao Z, Lu P. Correlation between methylation of human papillomavirus-16\u2009L1 gene and cervical carcinoma in Uyghur women. Gynecol Obstet Investig. 2017;82:22\u20139.","journal-title":"Gynecol Obstet Investig"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","volume":"24","author":"MA Clarke","year":"2018","unstructured":"Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women. Clin Cancer Res. 2018;24:2194\u2013202.","journal-title":"Clin Cancer Res"},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1042\/CS20160786","volume":"131","author":"SV Graham","year":"2017","unstructured":"Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond). 2017;131:2201\u201321.","journal-title":"Clin Sci (Lond)"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","volume":"2","author":"M Schiffman","year":"2016","unstructured":"Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.","journal-title":"Nat Rev Dis Primers"},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/ijc.29877","volume":"138","author":"M Valdez","year":"2016","unstructured":"Valdez M, Jeronimo J, Bansil P, Qiao YL, Zhao FH, Chen W, et al. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china. Int J Cancer. 2016;138:1453\u201361.","journal-title":"Int J Cancer"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/ijc.30807","volume":"141","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Dong L, Hu S, Feng R, Zhang X, Pan Q, et al. Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer. 2017;141:1110\u20139.","journal-title":"Int J Cancer"},{"key":"853_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ijc.31633","volume":"144","author":"R Rezhake","year":"2019","unstructured":"Rezhake R, Hu S-Y, Zhao S, Xu X-Q, Zhao X-L, Zhang L, et al. Eight-type human papillomavirus E6\/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. Int J Cancer. 2019;144:34\u201342.","journal-title":"Int J Cancer"},{"key":"853_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.virol.2013.07.016","volume":"445","author":"E Johannsen","year":"2013","unstructured":"Johannsen E, Lambert PF. Epigenetics of human papillomaviruses. Virology. 2013;445:205\u201312.","journal-title":"Virology."},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1128\/JCM.01106-13","volume":"51","author":"E Jacquin","year":"2013","unstructured":"Jacquin E, Baraquin A, Ramanah R, Carcopino X, Morel A, Valmary-Degano S, et al. Methylation of human papillomavirus type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR. J Clin Microbiol. 2013;51:3207\u201315.","journal-title":"J Clin Microbiol"},{"key":"853_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ijc.31539","volume":"143","author":"LMA De Strooper","year":"2018","unstructured":"De Strooper LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, Snijders PJF, Meijer C, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4\/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14\u2009year follow-up. Int J Cancer. 2018;143:1541\u20138.","journal-title":"Int J Cancer"},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ygyno.2011.01.013","volume":"121","author":"C Sun","year":"2011","unstructured":"Sun C, Reimers LL, Burk RD. Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol. 2011;121:59\u201363.","journal-title":"Gynecol Oncol"},{"key":"853_CR28","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e56","volume":"28","author":"YW Hsu","year":"2017","unstructured":"Hsu YW, Huang RL, Su PH, Chen YC, Wang HC, Liao CC, et al. Genotype-specific methylation of HPV in cervical intraepithelial neoplasia. J Gynecol Oncol. 2017;28:e56.","journal-title":"J Gynecol Oncol"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ygyno.2011.08.004","volume":"123","author":"D Mazumder Indra","year":"2011","unstructured":"Mazumder Indra D, Singh RK, Mitra S, Dutta S, Chakraborty C, Basu PS, et al. Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6\/E7 expression and associate with disease progression. Gynecol Oncol. 2011;123:597\u2013604.","journal-title":"Gynecol Oncol"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/onc.2009.517","volume":"29","author":"AF Fernandez","year":"2010","unstructured":"Fernandez AF, Esteller M. Viral epigenomes in human tumorigenesis. Oncogene. 2010;29:1405\u201320.","journal-title":"Oncogene."},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/ijc.27906","volume":"132","author":"A Chaiwongkot","year":"2013","unstructured":"Chaiwongkot A, Vinokurova S, Pientong C, Ekalaksananan T, Kongyingyoes B, Kleebkaow P, et al. Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer. 2013;132:2087\u201394.","journal-title":"Int J Cancer"},{"key":"853_CR32","doi-asserted-by":"crossref","unstructured":"Fertey J, Hagmann J, Ruscheweyh HJ, Munk C, Kjaer S, Huson D, et al. Methylation of CpG 5962 in L1 of the human papillomavirus 16 genome as a potential predictive marker for viral persistence: a prospective large cohort study using cervical swab samples. Cancer Med. 2019.","DOI":"10.1002\/cam4.2771"},{"key":"853_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.2192","volume":"212","author":"M Pett","year":"2007","unstructured":"Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007;212:356\u201367.","journal-title":"J Pathol"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1940-6207.CAPR-13-0091","volume":"6","author":"FH Zhao","year":"2013","unstructured":"Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013;6:938\u201348.","journal-title":"Cancer Prev Res (Phila)"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/ijc.31976","volume":"144","author":"DA Cook","year":"2019","unstructured":"Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 2019;144:2587\u201395.","journal-title":"Int J Cancer"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/jnci\/djs425","volume":"104","author":"N Wentzensen","year":"2012","unstructured":"Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst. 2012;104:1738\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"853_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcv.2013.12.014","volume":"59","author":"N Vasiljevic","year":"2014","unstructured":"Vasiljevic N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A. A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. J Clin Virol. 2014;59:161\u20136.","journal-title":"J Clin Virol"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ijc.30008","volume":"138","author":"AT Lorincz","year":"2016","unstructured":"Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016;138:2745\u201351.","journal-title":"Int J Cancer"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jcv.2013.06.026","volume":"58","author":"I Murakami","year":"2013","unstructured":"Murakami I, Fujii T, Dan K, Saito M, Ohno A, Iwata T, et al. Methylation of human papillomavirus-52 and -58 is a candidate biomarker in cervical neoplasia. J Clin Virol. 2013;58:149\u201354.","journal-title":"J Clin Virol"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ijc.28790","volume":"135","author":"AR Brentnall","year":"2014","unstructured":"Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer. 2014;135:1425\u201332.","journal-title":"Int J Cancer"},{"key":"853_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3233\/CBM-150507","volume":"15","author":"AR Brentnall","year":"2015","unstructured":"Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, et al. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \\textit{EPB41L3} methylation classifier. Cancer Biomark. 2015;15:669\u201375.","journal-title":"Cancer Biomark"},{"key":"853_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(08)70110-4","volume":"9","author":"M Schiffman","year":"2008","unstructured":"Schiffman M, Rodriguez AC. Heterogeneity in CIN3 diagnosis. Lancet Oncol. 2008;9:404\u20136.","journal-title":"Lancet Oncol"},{"key":"853_CR43","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1002\/ijc.27485","volume":"131","author":"P Guan","year":"2012","unstructured":"Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349\u201359.","journal-title":"Int J Cancer"},{"key":"853_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1006\/gyno.2001.6370","volume":"83","author":"J Belinson","year":"2001","unstructured":"Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439\u201344.","journal-title":"Gynecol Oncol"},{"key":"853_CR45","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/IGC.0b013e318286a95d","volume":"23","author":"SM Wang","year":"2013","unstructured":"Wang SM, Colombara D, Shi JF, Zhao FH, Li J, Chen F, et al. Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. Int J Gynecol Cancer. 2013;23:716\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"853_CR46","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/aje\/kwp188","volume":"170","author":"JF Shi","year":"2009","unstructured":"Shi JF, Belinson JL, Zhao FH, Pretorius RG, Li J, Ma JF, et al. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. Am J Epidemiol. 2009;170:708\u201316.","journal-title":"Am J Epidemiol"},{"key":"853_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1158\/1940-6207.CAPR-17-0088","volume":"10","author":"L Dong","year":"2017","unstructured":"Dong L, Hu SY, Zhang Q, Feng RM, Zhang L, Zhao XL, et al. Risk prediction of cervical cancer and precancers by type-specific human papillomavirus: evidence from a population-based cohort study in China. Cancer Prev Res (Phila). 2017;10:745\u201351.","journal-title":"Cancer Prev Res (Phila)"},{"key":"853_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ygyno.2017.11.016","volume":"148","author":"L Dong","year":"2018","unstructured":"Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q, et al. Human papillomavirus viral load as a useful triage tool for non-16\/18 high-risk human papillomavirus positive women: a prospective screening cohort study. Gynecol Oncol. 2018;148:103\u201310.","journal-title":"Gynecol Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-020-00853-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T19:19:30Z","timestamp":1620328770000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00853-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00853-1","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Cancer Institute\/Hospital, Chinese Academy of Medical Sciences (CICAMS). All patients signed informed consent before being included in this study, and their personal data were maintained confidential during this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}